Form 4: Neumora Therapeutics Head of R&D, Robert A. Lenz, Sells Shares Under 10b5-1 Trading Plan
SEC Form 4 Filing
Robert A. Lenz, Head of R&D at Neumora Therapeutics, sold shares of common stock on September 17 and 18, 2024, under a pre-arranged 10b5-1 trading plan.
Summary
- Robert A. Lenz, Head of R&D at Neumora Therapeutics, sold shares of the company's common stock on September 17 and 18, 2024.
- The sales were executed under a Rule 10b5-1 trading plan adopted on June 12, 2024.
- On September 17, 2024, 30,788 shares were sold at a weighted average price of $11.8142 per share.
- On September 18, 2024, 10,676 shares were sold at a weighted average price of $12.0917 per share.
- Following these transactions, Lenz directly owns 328,529 shares of Neumora Therapeutics common stock.
Sentiment
Score: 5
Explanation: The document is a standard SEC Form 4 filing, indicating insider trading activity. The sentiment is neutral as it simply reports transactions without expressing any positive or negative outlook.
Industry Context
Sales by company insiders are a common occurrence, and the use of 10b5-1 trading plans allows insiders to sell shares over a period of time while avoiding concerns about insider trading. The market typically views these sales in the context of the overall holdings of the insider and the reasons for establishing the trading plan.
Stakeholder Impact
- Shareholders may react to the insider selling activity, although the existence of a 10b5-1 plan mitigates concerns about opportunistic trading.
- The company's reputation could be affected depending on how the market interprets the insider's actions.
Key Dates
| Date | Description |
|---|---|
| 06/12/2024 | Date of adoption of Rule 10b5-1 trading plan. |
| 09/17/2024 | Date of first reported transaction: sale of 30,788 shares. |
| 09/18/2024 | Date of second reported transaction: sale of 10,676 shares. |
| 09/19/2024 | Date of Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.